Compare CAPT & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPT | SNGX |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.0M |
| IPO Year | N/A | 2006 |
| Metric | CAPT | SNGX |
|---|---|---|
| Price | $0.42 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 152.1K | 107.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $1.02 |
| 52 Week High | $1.93 | $6.23 |
| Indicator | CAPT | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 56.30 |
| Support Level | $0.40 | $1.19 |
| Resistance Level | $0.46 | $1.47 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 43.40 | 75.34 |
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).